Eckert & Ziegler raises profit expectations
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Change in Forecast/Disposal
30.06.2015 16:43
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad-hoc press release in accordance with Section 15 WpHG ISIN DE 0005659700
Eckert & Ziegler raises profit expectations
Berlin, June 30, 2015 - The sale of the shares in Berlin-based OctreoPharm Sciences GmbH to the French pharmaceuticals company IPSEN took legal effect today following the receipt of an initial payment. As a result, the Executive Board of Eckert & Ziegler AG has raised its profit forecast for 2015 to at least EUR 2.00 per share, or just over EUR 10 million. The new forecast is based on the probability-weighted anticipated income from the sale of the shares as well as current developments in the first half of the year.
More detailed information on the effect of the sale of shares on profits as well as the complete results for the first half of the year will be released as scheduled on August 4, 2015.
For enquiries, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de
30.06.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
End of Announcement DGAP News-Service